CH680002A5 - - Google Patents

Download PDF

Info

Publication number: CH680002A5
Authority: CH; Switzerland
Prior art keywords: tgf; amino acid; growth factor; nucleotide; transforming growth
Prior art date: 1987-10-06

Application number

CH3702/88A

Other languages

English (en)

French (fr)

Inventor

Anthony F Purchio

Linda Madisen

Nancy Webb

Original Assignee

Oncogen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-06

Filing date

1988-10-05

Publication date

1992-05-29

1988-10-05 Application filed by Oncogen filed Critical Oncogen

1992-05-29 Publication of CH680002A5 publication Critical patent/CH680002A5/fr

Links

101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 185
102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 181
210000004027 cell Anatomy 0.000 claims description 99
239000002243 precursor Substances 0.000 claims description 87
125000003729 nucleotide group Chemical group 0.000 claims description 69
108090000623 proteins and genes Proteins 0.000 claims description 63
102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 59
101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 59
239000002773 nucleotide Substances 0.000 claims description 56
108091026890 Coding region Proteins 0.000 claims description 49
238000000034 method Methods 0.000 claims description 33
125000003275 alpha amino acid group Chemical group 0.000 claims description 30
230000014509 gene expression Effects 0.000 claims description 28
235000018102 proteins Nutrition 0.000 claims description 27
102000004169 proteins and genes Human genes 0.000 claims description 27
125000000539 amino acid group Chemical group 0.000 claims description 26
229940072041 transforming growth factor beta 2 Drugs 0.000 claims description 22
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 14
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
229960000485 methotrexate Drugs 0.000 claims description 11
239000003550 marker Substances 0.000 claims description 10
108090000765 processed proteins & peptides Proteins 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 9
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 8
235000009582 asparagine Nutrition 0.000 claims description 8
229960001230 asparagine Drugs 0.000 claims description 8
108010022394 Threonine synthase Proteins 0.000 claims description 7
230000002950 deficient Effects 0.000 claims description 7
102000004419 dihydrofolate reductase Human genes 0.000 claims description 7
230000012010 growth Effects 0.000 claims description 6
230000001131 transforming effect Effects 0.000 claims description 4
229940099456 transforming growth factor beta 1 Drugs 0.000 claims description 4
239000003102 growth factor Substances 0.000 claims description 3
102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
210000003527 eukaryotic cell Anatomy 0.000 claims 18
229940024606 amino acid Drugs 0.000 description 41
235000001014 amino acid Nutrition 0.000 description 41
150000001413 amino acids Chemical class 0.000 description 40
239000002299 complementary DNA Substances 0.000 description 35
239000000523 sample Substances 0.000 description 25
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 22
108090001012 Transforming Growth Factor beta Proteins 0.000 description 21
239000012634 fragment Substances 0.000 description 21
108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
102000004887 Transforming Growth Factor beta Human genes 0.000 description 20
239000000047 product Substances 0.000 description 19
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 19
108020004414 DNA Proteins 0.000 description 18
239000002609 medium Substances 0.000 description 16
238000003780 insertion Methods 0.000 description 15
230000037431 insertion Effects 0.000 description 15
108010076504 Protein Sorting Signals Proteins 0.000 description 13
239000013604 expression vector Substances 0.000 description 13
108020004999 messenger RNA Proteins 0.000 description 13
238000013519 translation Methods 0.000 description 13
238000013518 transcription Methods 0.000 description 12
230000035897 transcription Effects 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
238000010367 cloning Methods 0.000 description 11
229960001603 tamoxifen Drugs 0.000 description 11
101150074155 DHFR gene Proteins 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
238000000636 Northern blotting Methods 0.000 description 9
241000700605 Viruses Species 0.000 description 9
238000003776 cleavage reaction Methods 0.000 description 9
230000007017 scission Effects 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
238000012217 deletion Methods 0.000 description 8
230000037430 deletion Effects 0.000 description 8
235000006109 methionine Nutrition 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
230000009466 transformation Effects 0.000 description 8
238000011144 upstream manufacturing Methods 0.000 description 8
101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
229930182817 methionine Natural products 0.000 description 7
239000000203 mixture Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
239000013598 vector Substances 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
230000013595 glycosylation Effects 0.000 description 6
238000006206 glycosylation reaction Methods 0.000 description 6
239000000178 monomer Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
230000006337 proteolytic cleavage Effects 0.000 description 5
230000028327 secretion Effects 0.000 description 5
238000001262 western blot Methods 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
102000004594 DNA Polymerase I Human genes 0.000 description 4
108010017826 DNA Polymerase I Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
241001131785 Escherichia coli HB101 Species 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
201000005825 prostate adenocarcinoma Diseases 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
241000722895 Callitriche Species 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000001772 blood platelet Anatomy 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
244000309466 calf Species 0.000 description 3
238000010276 construction Methods 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
239000005546 dideoxynucleotide Substances 0.000 description 3
230000029087 digestion Effects 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
230000037452 priming Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
238000007900 DNA-DNA hybridization Methods 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
241000256248 Spodoptera Species 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000007792 addition Methods 0.000 description 2
230000002788 anti-peptide Effects 0.000 description 2
230000027455 binding Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000009432 framing Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
201000011216 nasopharynx carcinoma Diseases 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
WVRUNFYJIHNFKD-WDSKDSINSA-N Arg-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N WVRUNFYJIHNFKD-WDSKDSINSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108700003483 Drosophila dpp Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
102000002746 Inhibins Human genes 0.000 description 1
108010004250 Inhibins Proteins 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
241001045988 Neogene Species 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
108700040121 Protein Methyltransferases Proteins 0.000 description 1
102000055027 Protein Methyltransferases Human genes 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
102000043168 TGF-beta family Human genes 0.000 description 1
108091085018 TGF-beta family Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
-1 acids Amines Chemical class 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012595 freezing medium Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
210000004293 human mammary gland Anatomy 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
238000002169 hydrotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000012528 membrane Substances 0.000 description 1
150000002741 methionine derivatives Chemical class 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
150000002742 methionines Chemical class 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
210000002568 pbsc Anatomy 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000004262 preparative liquid chromatography Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229960002429 proline Drugs 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000003760 tallow Substances 0.000 description 1
235000013616 tea Nutrition 0.000 description 1
230000005758 transcription activity Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CH3702/88A 1987-10-06 1988-10-05 CH680002A5 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US10675287A	1987-10-06	1987-10-06
US14826788A	1988-01-25	1988-01-25
US23406588A	1988-08-18	1988-08-18

Publications (1)

Publication Number	Publication Date
CH680002A5 true CH680002A5 (de)	1992-05-29

Family

ID=27380183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH3702/88A CH680002A5 (de)	1987-10-06	1988-10-05

Country Status (22)

Country	Link
JP (1)	JPH02444A (de)
KR (1)	KR970001236B1 (de)
CN (1)	CN1035845A (de)
AT (1)	AT398433B (de)
BE (1)	BE1002693A5 (de)
CH (1)	CH680002A5 (de)
DE (1)	DE3833897C2 (de)
DK (1)	DK556388A (de)
ES (1)	ES2012556A6 (de)
FI (1)	FI884546A7 (de)
FR (1)	FR2621324B1 (de)
GB (1)	GB2210620B8 (de)
GR (1)	GR1000492B (de)
IE (1)	IE60918B1 (de)
IL (1)	IL87877A0 (de)
IT (1)	IT1227957B (de)
MY (1)	MY103779A (de)
NL (1)	NL8802442A (de)
NO (1)	NO884429L (de)
NZ (1)	NZ226486A (de)
PT (1)	PT88670B (de)
SE (1)	SE8803528L (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5221620A (en) *	1987-10-06	1993-06-22	Oncogen	Cloning and expression of transforming growth factor β2
US5445941A (en) *	1993-06-21	1995-08-29	Eli Lilly And Company	Method for screening anti-osteoporosis agents
CN100389120C (zh) *	2005-04-12	2008-05-21	中国人民解放军第三军医大学野战外科研究所	封闭TGF－β1的反义寡核苷酸及其在制备治疗纤维化相关疾病药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0169016B2 (de) *	1984-07-16	2004-04-28	Celtrix Pharmaceuticals, Inc.	Knorpel-induzierende Polypeptid-Faktoren aus Knochen
IL78197A (en) *	1985-03-22	1991-07-18	Genentech Inc	Nucleic acid encoding tgf-beta and its uses
PT86144B (pt) *	1986-11-17	1990-08-31	Sandoz Sa	Processo para a preparacao de uma proteina tendo actividade semelhante a factor g-tsf humano e de composicoes farmaceuticas que o contem
US4931548A (en) *	1987-01-30	1990-06-05	Techne Corporation	Heterodimer form of transforming growth factor-beta
WO1988005787A1 (en) *	1987-01-30	1988-08-11	Techne Corporation	Transforming growth factor-beta
AU1539188A (en) *	1987-05-04	1988-11-10	Bristol-Myers Squibb Company	TGF-B2 and novel compositions having anti-neoplastic activity

1988
- 1988-09-29 IL IL87877A patent/IL87877A0/xx active Protection Beyond IP Right Term
- 1988-10-03 FI FI884546A patent/FI884546A7/fi not_active IP Right Cessation
- 1988-10-04 MY MYPI88001108A patent/MY103779A/en unknown
- 1988-10-04 PT PT88670A patent/PT88670B/pt not_active IP Right Cessation
- 1988-10-05 KR KR1019880012986A patent/KR970001236B1/ko not_active Expired - Lifetime
- 1988-10-05 AT AT0245488A patent/AT398433B/de not_active IP Right Cessation
- 1988-10-05 CH CH3702/88A patent/CH680002A5/fr not_active IP Right Cessation
- 1988-10-05 NO NO88884429A patent/NO884429L/no unknown
- 1988-10-05 NL NL8802442A patent/NL8802442A/nl not_active Application Discontinuation
- 1988-10-05 FR FR8813046A patent/FR2621324B1/fr not_active Expired - Fee Related
- 1988-10-05 BE BE8801141A patent/BE1002693A5/fr not_active IP Right Cessation
- 1988-10-05 SE SE8803528A patent/SE8803528L/ not_active Application Discontinuation
- 1988-10-05 DE DE3833897A patent/DE3833897C2/de not_active Expired - Fee Related
- 1988-10-05 ES ES8803023A patent/ES2012556A6/es not_active Expired - Lifetime
- 1988-10-05 CN CN88109075A patent/CN1035845A/zh active Pending
- 1988-10-05 GR GR880100660A patent/GR1000492B/el unknown
- 1988-10-05 DK DK556388A patent/DK556388A/da not_active Application Discontinuation
- 1988-10-05 IE IE301888A patent/IE60918B1/en not_active IP Right Cessation
- 1988-10-06 IT IT8822213A patent/IT1227957B/it active
- 1988-10-06 GB GB8823448A patent/GB2210620B8/en not_active Expired - Fee Related
- 1988-10-06 NZ NZ226486A patent/NZ226486A/xx unknown
- 1988-10-06 JP JP63251011A patent/JPH02444A/ja active Pending

Also Published As

Publication number	Publication date
GB2210620B (en)	1992-07-08
MY103779A (en)	1993-09-30
GB8823448D0 (en)	1988-11-16
IT1227957B (it)	1991-05-20
NL8802442A (nl)	1989-05-01
SE8803528L (sv)	1989-04-07
DK556388D0 (da)	1988-10-05
FR2621324A1 (fr)	1989-04-07
SE8803528D0 (sv)	1988-10-05
IL87877A0 (en)	1989-03-31
KR890006814A (ko)	1989-06-16
NO884429D0 (no)	1988-10-05
BE1002693A5 (fr)	1991-05-07
DK556388A (da)	1989-04-07
DE3833897A1 (de)	1989-05-03
IE60918B1 (en)	1994-08-24
IT8822213A0 (it)	1988-10-06
AT398433B (de)	1994-12-27
ES2012556A6 (es)	1990-04-01
GB2210620B8 (en)	1995-07-17
FR2621324B1 (fr)	1994-02-18
ATA245488A (de)	1994-04-15
IE883018L (en)	1989-04-06
CN1035845A (zh)	1989-09-27
GR1000492B (el)	1992-07-30
FI884546A7 (fi)	1989-04-07
JPH02444A (ja)	1990-01-05
DE3833897C2 (de)	1997-03-20
KR970001236B1 (ko)	1997-02-04
NZ226486A (en)	1991-08-27
FI884546A0 (fi)	1988-10-03
NO884429L (no)	1989-04-07
PT88670B (pt)	1992-12-31
GB2210620A (en)	1989-06-14

Legal Events

Date	Code	Title	Description
1998-06-15	PL	Patent ceased

Publication	Publication Date	Title
AU640115B2 (en)	1993-08-19	Cloning and expression of transforming growth factor beta-2
KR100214740B1 (ko)	1999-08-02	골유도조성물
AU704910B2 (en)	1999-05-06	Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)
JPH08277227A (ja)	1996-10-22	上皮細胞に特異的な成長因子をコードするｄｎａ
DE68918248T2 (de)	1995-05-04	TGF beta 1/beta2: ein chimärer transformierender Wachstumsfaktor.
US5935852A (en)	1999-08-10	DNA molecules encoding mammalian cerberus-like proteins
EP0293785A2 (de)	1988-12-07	Klonierung und Expression von transformierendem Affenwachstumsfaktor-SS 1
WO1998020029A2 (en)	1998-05-14	Hnf3-delta compositions
Hallböök et al.	1988	Production and characterization of biologically active recombinant beta nerve growth factor
JPH03130089A (ja)	1991-06-03	サル変換成長因子―β１のクローニング及び発現
CH680002A5 (de)	1992-05-29
LU87361A1 (fr)	1989-05-08	Sequence nucleotidique codant pour le precurseur du facteur de croissance transformant beta2,precurseur du facteur de croissance transformant beta2,et facteur de croissance transformant beta2
AU630075B2 (en)	1992-10-22	Cloning and expression of transforming growth factor 2b
EP0686194B1 (de)	2003-07-09	Wachtumsfaktor aus der harp-reihe, verfahren zu ihrer herstellung und verwendungen davon
US20220402985A1 (en)	2022-12-22	ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3
IL103749A (en)	1994-12-29	Method for production of transforming growth factor beta 2
CN1129805A (zh)	1996-08-28	人促血小板生成素变异体、其cDNA克隆表达及检测方法
US5844085A (en)	1998-12-01	Cloning and expression of simian transforming growth factor β1
JPH08198899A (ja)	1996-08-06	新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
JPH08301898A (ja)	1996-11-19	新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
JPH0556783A (ja)	1993-03-09	変換成長因子β２のクローニングおよび発現